Tobira Therapeutics, Inc. (Inactive) (extinct)

Tobira Therapeutics, Inc. (Inactive) (extinct)

Tobira Therapeutics, Inc. (Inactive) (extinct)

Overview
Date Founded

2006

Headquarters

701 Gateway Boulevard, Suite 200, South San Francisco, CA, 94080, USA

Type of Company

Private

Industries

Pharmaceuticals
Medical Support Services

Company Description

Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA.

Executives & Employees

President, Chief Executive Officer & Director

Paths to Tobira Therapeutics, Inc. (Inactive)
Potential Connections via
Relationship Science
You
Tobira Therapeutics, Inc. (Inactive)
Recent Transactions
Details Hidden

Regado Biosciences, Inc. purchases Tobira Therapeutics, Inc. (Inactive) from Frazier Management LLC, Canaan Management, Inc., Domain Associates LLC, Montreux Equity Partners, Novo Ventures resulting in a new company Tobira Therapeutics, Inc.

Details Hidden

Tobira Therapeutics, Inc. (Inactive) raised money in a private placement transaction

Details Hidden

Tobira Therapeutics, Inc. (Inactive) raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onRegado Biosciences, Inc. purchases Tobira Therapeutics, Inc. (Inactive) from Frazier Management LLC, Canaan Management, Inc., Domain Associates LLC, Montreux Equity Partners, Novo Ventures resulting in a new company Tobira Therapeutics, Inc.

Investment Advisor

Advised onRegado Biosciences, Inc. purchases Tobira Therapeutics, Inc. (Inactive) from Frazier Management LLC, Canaan Management, Inc., Domain Associates LLC, Montreux Equity Partners, Novo Ventures resulting in a new company Tobira Therapeutics, Inc.

Investment Advisor

Advised onRegado Biosciences, Inc. purchases Tobira Therapeutics, Inc. (Inactive) from Frazier Management LLC, Canaan Management, Inc., Domain Associates LLC, Montreux Equity Partners, Novo Ventures resulting in a new company Tobira Therapeutics, Inc.

Founding Partner

Advised onRegado Biosciences, Inc. purchases Tobira Therapeutics, Inc. (Inactive) from Frazier Management LLC, Canaan Management, Inc., Domain Associates LLC, Montreux Equity Partners, Novo Ventures resulting in a new company Tobira Therapeutics, Inc.

Investors
Details Hidden

Executive Officer at Cirius Therapeutics, Inc.

Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds' investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tobira Therapeutics, Inc. (Inactive). The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tobira Therapeutics, Inc. (Inactive)'s profile does not indicate a business or promotional relationship of any kind between RelSci and Tobira Therapeutics, Inc. (Inactive).